Steven Nichtberger, Cabaletta Bio CEO

Ca­balet­ta lands $84M from stock sale af­ter FDA clears INDs for CD19 CAR-T in au­toim­mune dis­eases

With the FDA’s clear­ance to put its CD19 CAR-T in­to two clin­i­cal tri­als for au­toim­mune dis­eases, Ca­balet­ta Bio has scored

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA